Telix to buy ITM for US$1.65 billion upfront, with up to US$700 million in milestones
AI Market Summary
Telix Pharmaceuticals announced a transformative acquisition of ITM for US$1.65B upfront plus up to US$700M milestones, targeting vertical integration in radiopharmaceuticals and a pro forma 2026 revenue base above US$1.3B. The news is strategically positive at the company level, but completion is contingent on shareholder and regulatory approvals with a long timeline to FY2026 end, limiting immediate broader market spillover.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-0.16%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
Telix Pharmaceuticals said it will acquire 100% of ITM for US$1.65 billion upfront, with up to US$700 million in milestone payments. ITM reported US$273 million in 2025 revenue and a 40% CAGR from 2021–2025. On a pro forma basis, the combined group is projected to generate more than US$1.3 billion in 2026 revenue, with Telix shareholders expected to own about 76.3% after completion. The deal remains subject to shareholder and regulatory approvals, with closing expected by the end of FY2026.
